JP7505788B2 - C9orf72に由来するジペプチドリピートタンパク質に対して指向化されたペプチド免疫原コンストラクト - Google Patents

C9orf72に由来するジペプチドリピートタンパク質に対して指向化されたペプチド免疫原コンストラクト Download PDF

Info

Publication number
JP7505788B2
JP7505788B2 JP2021542077A JP2021542077A JP7505788B2 JP 7505788 B2 JP7505788 B2 JP 7505788B2 JP 2021542077 A JP2021542077 A JP 2021542077A JP 2021542077 A JP2021542077 A JP 2021542077A JP 7505788 B2 JP7505788 B2 JP 7505788B2
Authority
JP
Japan
Prior art keywords
seq
dpr
lys
peptide
peptide immunogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021542077A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511995A (ja
JP2022511995A5 (cg-RX-API-DMAC7.html
Inventor
イ ワン、チャン
ヴェルマ、アジャイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Neuroscience Ltd Cayman Islands
Original Assignee
United Neuroscience Ltd Cayman Islands
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Neuroscience Ltd Cayman Islands filed Critical United Neuroscience Ltd Cayman Islands
Publication of JP2022511995A publication Critical patent/JP2022511995A/ja
Publication of JP2022511995A5 publication Critical patent/JP2022511995A5/ja
Application granted granted Critical
Publication of JP7505788B2 publication Critical patent/JP7505788B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Computational Biology (AREA)
JP2021542077A 2018-10-01 2019-10-01 C9orf72に由来するジペプチドリピートタンパク質に対して指向化されたペプチド免疫原コンストラクト Active JP7505788B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862739794P 2018-10-01 2018-10-01
US62/739,794 2018-10-01
PCT/US2019/053967 WO2020072428A1 (en) 2018-10-01 2019-10-01 Peptide immunogen constructs directed against dipeptide repeat proteins from c9orf72

Publications (3)

Publication Number Publication Date
JP2022511995A JP2022511995A (ja) 2022-02-01
JP2022511995A5 JP2022511995A5 (cg-RX-API-DMAC7.html) 2022-10-05
JP7505788B2 true JP7505788B2 (ja) 2024-06-25

Family

ID=70055826

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021542077A Active JP7505788B2 (ja) 2018-10-01 2019-10-01 C9orf72に由来するジペプチドリピートタンパク質に対して指向化されたペプチド免疫原コンストラクト

Country Status (8)

Country Link
US (1) US20210347866A1 (cg-RX-API-DMAC7.html)
EP (1) EP3861007A4 (cg-RX-API-DMAC7.html)
JP (1) JP7505788B2 (cg-RX-API-DMAC7.html)
CN (1) CN113227116A (cg-RX-API-DMAC7.html)
AU (1) AU2019354291A1 (cg-RX-API-DMAC7.html)
CA (1) CA3114657A1 (cg-RX-API-DMAC7.html)
TW (1) TWI781347B (cg-RX-API-DMAC7.html)
WO (1) WO2020072428A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018342105B2 (en) 2017-09-26 2023-11-16 University Of Florida Research Foundation, Incorporated Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
US20230218730A1 (en) * 2019-09-23 2023-07-13 University Of Florida Research Foundation, Incorporated Vaccine therapy for ran protein diseases
WO2021072187A2 (en) 2019-10-10 2021-04-15 University Of Florida Research Foundation, Incorporated Ran proteins as biomarkers in cag/ctg expansion disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003504302A (ja) 1998-06-20 2003-02-04 ユナイティド バイオメディカル インコーポレイティド 合成ペプチド免疫原のための免疫刺激因子としての人工的tヘルパー細胞エピトープ
WO2014116865A1 (en) 2013-01-24 2014-07-31 Mayo Foundation For Medical Education And Research Methods and materials for detecting c9orf72 hexanucleotide repeat expansion positive frontotemporal lobar degeneration or c9orf72 hexanucleotide repeat expansion positive amyotrophic lateral sclerosis
JP2016513638A (ja) 2013-03-15 2016-05-16 ユナイテッド・バイオメディカル・インコーポレーテッドUnited Biomedical Incorporated アルツハイマー型認知症の予防用及び免疫療法用ペプチドワクチン
JP2017538665A (ja) 2014-09-30 2017-12-28 ニューリミューン ホールディング エイジー ヒト由来の抗ジペプチドリピート(dpr)抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
GB0510763D0 (en) * 2005-05-27 2005-06-29 London School Hygiene & Tropical Medicine Malaria vaccines
RS59283B1 (sr) * 2013-01-22 2019-10-31 Deutsches Zentrum Fuer Neurodegenerative Erkrankungen E V Proteini sa dipeptidnim ponovkom kao terapeutsko ciljno mesto kod neurodegenerativnih bolesti sa ekspanzijom heksanukleotidnog ponovka
MY192689A (en) * 2013-10-11 2022-09-01 Ionis Pharmaceuticals Inc Compositions for modulating c9orf72 expression

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003504302A (ja) 1998-06-20 2003-02-04 ユナイティド バイオメディカル インコーポレイティド 合成ペプチド免疫原のための免疫刺激因子としての人工的tヘルパー細胞エピトープ
WO2014116865A1 (en) 2013-01-24 2014-07-31 Mayo Foundation For Medical Education And Research Methods and materials for detecting c9orf72 hexanucleotide repeat expansion positive frontotemporal lobar degeneration or c9orf72 hexanucleotide repeat expansion positive amyotrophic lateral sclerosis
JP2016513638A (ja) 2013-03-15 2016-05-16 ユナイテッド・バイオメディカル・インコーポレーテッドUnited Biomedical Incorporated アルツハイマー型認知症の予防用及び免疫療法用ペプチドワクチン
JP2017538665A (ja) 2014-09-30 2017-12-28 ニューリミューン ホールディング エイジー ヒト由来の抗ジペプチドリピート(dpr)抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Vaccine,2005年,Vol.23,p.2049-2056

Also Published As

Publication number Publication date
WO2020072428A1 (en) 2020-04-09
US20210347866A1 (en) 2021-11-11
JP2022511995A (ja) 2022-02-01
EP3861007A1 (en) 2021-08-11
CA3114657A1 (en) 2020-04-09
TWI781347B (zh) 2022-10-21
AU2019354291A1 (en) 2021-05-06
CN113227116A (zh) 2021-08-06
TW202028223A (zh) 2020-08-01
EP3861007A4 (en) 2022-07-13

Similar Documents

Publication Publication Date Title
US11773148B2 (en) Tau peptide immunogen constructs
AU2019404226A1 (en) Artificial promiscuous T helper cell epitopes as immune stimulators for synthetic peptide immunogens
JP7563765B2 (ja) カルシトニン遺伝子関連ペプチド(cgrp)を標的とするペプチド免疫原ならびに片頭痛の治療及び予防のためのそれらの配合物
AU2018383708B2 (en) Peptide immunogens of IL-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis
TWI781347B (zh) 針對源自c9orf72二肽重複蛋白的胜肽免疫原結構
AU2024212682A1 (en) Tau and amyloid beta peptide immunogen compositions and related methods
IT9019914A1 (it) Composti immunogenici, il procedimento per la loro sintesi e loro impiego per la preparazione di vaccini antimalaria
TWI823051B (zh) 針對垂體腺苷酸環化酶激活胜肽的胜肽免疫原及其預防和治療偏頭痛的製劑
HK40049481A (en) Peptide immunogen constructs directed against dipeptide repeat proteins from c9orf72
TW202142551A (zh) 針對pcsk9胜肽免疫原及其預防和治療pcsk9介導疾病的製劑
AU2023307073A1 (en) Tau peptide immunogen constructs
BR112020013352A2 (pt) imunógenos de peptídeo e formulações dos mesmos direcionados a ige ligada a membrana para tratamento de doenças alérgicas mediadas por ige
HK40022726A (zh) Tau肽免疫原构建体
HK40025696A (en) Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240508

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240606